Limited Local Lymph Node Excision Plus Radiotherapy May Be Effective in Melanoma

Share this content:
Previous studies have evaluated the effects of limited local node excision plus radiotherapy among patients with melanoma in this subgroup, but had conflicting results.
Previous studies have evaluated the effects of limited local node excision plus radiotherapy among patients with melanoma in this subgroup, but had conflicting results.

Limited local cervical lymph node excision followed by adjuvant radiotherapy may be an effective alternative to therapeutic complete lymph node dissection (TLCND) among patients who are elderly or have major comorbidities, according to a study published in the Annals of Surgical Oncology.1

TLCND is the recommended course of treatment among patients with positive metastatic melanoma in cervical lymph nodes, but has been associated with procedure-related morbidities and is contraindicated for elderly patients or those with significant comorbid conditions. Previous studies have evaluated the effects of limited local node excision plus radiotherapy, but have produced conflicting results.

For this retrospective analysis, researchers assessed the outcomes of 28 patients who underwent limited local node excision followed by adjuvant radiotherapy and who had undergone resection for head and neck melanoma or those with positive cervical lymph nodes with an unknown primary site. The median age of the study population was 78 years, and included patients with major comorbidities including ischemic heart disease, dementia, atrial fibrillation, diabetes mellitus, and advanced cerebrovascular disease.

After a median follow-up of 22 months, results showed that the 5-year regional control rate was 69%, the 5-year disease-free survival rate was 44%, and the overall survival rate was 50%.

At the time of analysis, 7 patients were alive; among the 21 patients who died during follow-up, the median survival was 16 months post-limited local node excision.

The authors concluded that “this treatment approach may be considered as a satisfactory pragmatic option in selected patients who are elderly and who have major comorbidities that make them poor candidates for TCLND. In the future, a study with prospectively collected data will be necessary to define the place of this combined treatment modality in this patient category.”

Reference

  1. Kroon HM, van der Bol WD, Tonks KT, Hong AM, Hruby G, Thompson JF. Treatment of clinically positive cervical lymph nodes by limited local node excision and adjuvant radiotherapy in melanoma patients with major comorbidities [published online August 16, 2018]. Ann Surg Oncol. doi: 10.1245/s10434-018-6692-2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs